{
  "first_published_at": "2011-01-12", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON105760", 
  "title": "Moxifloxacin: use in pelvic inflammatory disease only when other antibacterials are inappropriate or ineffective", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Infectious disease\"]}", 
  "_document_number": 168, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/change_icon.png", 
  "therapeutic_area": [
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Moxifloxacin: use in pelvic inflammatory disease only when other antibacterials are inappropriate or ineffective</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: January 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Moxifloxacin should only be used when other antibacterials are inappropriate or ineffective for treatment of mild to moderate pelvic inflammatory disease as well as treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community acquired pneumonia (except severe cases).-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Because of evidence of an increased risk of life-threatening liver reactions and other serious risks (such as QT interval prolongation), oral moxifloxacin (Avelox &#9660;, a fluoroquinolone antibiotic) should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of the infections below or when these have failed.</p><p>This restriction now applies to treatment of mild to moderate pelvic inflammatory disease as well as treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community acquired pneumonia (except severe cases).</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p><strong>Further information:</strong></p><p>Drug Safety Update, <a href=\"ssLINK/CON087781\">Aug 2008</a></p><p>BNF section 5.1.12 <a href=\"http://www.medicinescomplete.com/mc/bnf/current/3944.htm\" target=\"_blank\">Quinolones</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Jan 2011, vol 4 issue 6: S1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Because of evidence of an increased risk of life-threatening liver reactions and other serious risks (such as QT interval prolongation), oral moxifloxacin (Avelox &#9660;, a fluoroquinolone antibiotic) should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of the infections below or when these have failed.</p><p>This restriction now applies to treatment of mild to moderate pelvic inflammatory disease as well as treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community acquired pneumonia (except severe cases).</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p><strong>Further information:</strong></p><p>Drug Safety Update, <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON087781\">Aug 2008</a></p><p>BNF section 5.1.12 <a href=\"http://www.medicinescomplete.com/mc/bnf/current/3944.htm\" target=\"_blank\">Quinolones</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Jan 2011, vol 4 issue 6: S1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-01-01", 
  "date_last_modified": "2011-01-12", 
  "_assets": [], 
  "_item_id": 168, 
  "summary": "", 
  "body": "Article date: January 2011\n\nBecause of evidence of an increased risk of life-threatening liver reactions and other serious risks (such as QT interval prolongation), oral moxifloxacin (Avelox ▼, a fluoroquinolone antibiotic) should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of the infections below or when these have failed.\n\nThis restriction now applies to treatment of mild to moderate pelvic inflammatory disease as well as treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community acquired pneumonia (except severe cases).\n\nConsideration should be given to official guidance on the appropriate use of antibacterial agents.\n\nFurther information:\n\nDrug Safety Update, [Aug 2008](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON087781)\n\nBNF section 5.1.12 [Quinolones](http://www.medicinescomplete.com/mc/bnf/current/3944.htm)\n\n \n\nArticle citation: Drug Safety Update Jan 2011, vol 4 issue 6: S1.\n"
}